Article

Hospital-Wide Protocol Significantly Improved Appropriate Management of Patients with \textit{Staphylococcus aureus} Bloodstream Infection

Kawisara Krasaewes $^1$, Saowaluck Yasri $^1$, Phadungkiat Khamnoi $^2$ and Romanee Chaiwarith $^1$, *

Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Chiang Mai University, Chiang Mai 50200, Thailand; kawisara.k@cmu.ac.th (K.K.); saowaluckyasri@gmail.com (S.Y.)

Diagnostic Laboratory, Maharaj Nakorn Chiang Mai Hospital, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand; micromedcmu@hotmail.com

* Correspondence: rchaiwar@gmail.com; Tel.: +66-5393-6457

Abstract: Background: \textit{Staphylococcus aureus} bloodstream infection (SA-BSI) causes morbidity and mortality. We established a management protocol for patients with SA-BSI aimed at improving quality of care and patient outcomes. Methods: A retrospective pre–post intervention study was conducted at Maharaj Nakorn Chiang Mai Hospital from 1 October 2019 to 30 September 2020 in the pre-intervention period and from 1 November 2020 to 31 October 2021 in the post-intervention period. Results: Of the 169 patients enrolled, 88 were in the pre-intervention and 81 were in the post-intervention periods. There were similar demographic characteristics between the two periods. In the post-intervention period, evaluations for metastatic infections were performed more frequently, e.g., echocardiography (70.5% vs. 91.4%, \(p = 0.001\)). The appropriateness of antibiotic prescription was higher in the post-intervention period (42% vs. 81.5%, \(p < 0.001\)). The factors associated with the appropriateness of antibiotic prescription were ID consultation (OR 15.5; 95% CI = 5.9–40.8, \(p < 0.001\)), being in the post-intervention period (OR 9.4; 95% CI: 3.5–25.1, \(p < 0.001\)), and thorough investigations for metastatic infection foci (OR 7.2; 95% CI 2.1–25.2, \(p = 0.002\)). However, the 90-day mortality was not different (34.1% and 27.2% in the pre- and post-intervention periods, respectively). The factors associated with mortality from the multivariate analysis were the presence of alteration of consciousness (OR 11.24; 95% CI: 3.96–31.92, \(p < 0.001\)), having a malignancy (OR 6.64; 95% CI: 1.83–24.00, \(p = 0.004\)), hypoalbuminemia (OR 5.23; 95% CI: 1.71–16.02, \(p = 0.004\)), and having a respiratory tract infection (OR 5.07; 95% CI: 1.53–16.84, \(p = 0.008\)). Source control was the only factor that reduced the risk of death (OR 0.08; 95% CI: 0.01–0.53, \(p = 0.009\)). Conclusion: One-third of patients died. Hospital-wide protocol implementation significantly improved the quality of care. However, the mortality rate did not decrease.

Keywords: \textit{S. aureus}; bloodstream infection; bacteremia; quasi-experimental study

1. Introduction

\textit{Staphylococcus aureus} bloodstream infection (SA-BSI) has a mortality rate that ranges from 20 to 40% [1,2]. Poor clinical outcomes, including death, are associated with methicillin-resistant strains, dissemination to multiple organs, the elderly, multiple comorbidities, ICU admission, shock, and inappropriate empiric antibiotic treatment [1–5]. Infectious disease (ID) consultation and adherence to protocols have been shown to improve patient management, e.g., increasing the rate of echocardiography and reducing mortality [6–10]. However, studies have been performed in different hospital settings, and the treatment protocol showed some variations. ID specialists must be involved in the development of treatment protocols. However, ID consultations were not always mandated in the protocols.
of some studies [6–10]. The value of adherence to treatment protocols, ID consultations, or a combination of both is difficult to determine.

Maharaj Nakorn Chiang Mai Hospital, an affiliated hospital of Chiang Mai University, is a 1400-bed tertiary care referral center in Northern Thailand. There have been 80–90 patients with SA-BSI each year since 2013 (data from the Diagnostic Laboratory, Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand). The primary care team includes residents and attending physicians who are responsible for patient management and for consulting specialists if indicated. For example, with SA-BSI, the primary care team sometimes manages patients by themselves without ID consultation. To improve patient care, we therefore developed a hospital-wide protocol for the management of patients with SA-BSI.

The primary objective of this study was to determine the 90-day mortality rate of patients who had SA-BSI. The secondary objectives were to determine (1) the recurrent rate of SA-BSI; (2) the rate of appropriate management of SA-BSI, e.g., the rate of investigations for metastatic infections, the rate of follow-up blood culture at 72 h after receiving appropriate antibiotics; (3) the rate of appropriate of antibiotic prescription and factors associated with appropriateness; (4) risk factors for death.

2. Results

2.1. Demographic Characteristics

One-hundred and sixty-nine patients who had SA-BSI and met the inclusion criteria were enrolled (Figure 1). The pre-intervention and post-intervention period included 88 and 81 cases, respectively. Patients’ demographic characteristics were generally similar in both periods. In the pre-intervention period, fifty-one patients (58%) were male, and the median age was 64.5 years (IQR 56, 71.5). In the post-intervention period, fifty-one patients (63%) were male, and the median age was 63 years (IQR 50, 72). These characteristics were similar in both periods. Most patients were admitted to the general internal medicine unit. The three most common underlying diseases were hypertension, end-stage renal disease, and diabetes mellitus, respectively (Table 1).

![Figure 1. Flow diagram of the cases of *Staphylococcus aureus* bloodstream infection included in the study.](image-url)
Table 1. Demographic characteristics of patients who had *Staphylococcus aureus* bloodstream infections.

| Demographic Characteristics | Pre-Intervention Period (n = 88) | Post-Intervention Period (n = 81) | p-Value |
|-----------------------------|-----------------------------------|-----------------------------------|---------|
| Male                        | 51 (58)                           | 51 (63)                           | 0.506   |
| Age in years (median, IQR)  | 64.5 (56, 71.5)                   | 63 (50, 72)                       | 0.195   |
| Unit of admission           |                                   |                                   |         |
| General internal medicine   | 56 (63.6)                         | 49 (60.5)                         | 0.674   |
| Medical intensive care      | 11 (12.5)                         | 15 (18.5)                         | 0.279   |
| General surgery             | 11 (12.5)                         | 9 (11.1)                          | 0.780   |
| Surgical intensive care     | 4 (4.5)                           | 2 (2.5)                           | 0.683   |
| General orthopedic          | 5 (5.7)                           | 6 (7.4)                           | 0.650   |
| Orthopedics intensive care  | 1 (1.1)                           | 0 (0)                             | 1.000   |
| Underlying Diseases         |                                   |                                   | 0.852   |
| Hypertension                | 36 (45.6)                         | 39 (45.2)                         | 0.344   |
| End-stage renal disease     | 31 (39.2)                         | 35 (42.6)                         | 0.288   |
| Diabetes mellitus           | 28 (35.4)                         | 29 (34.6)                         | 0.584   |
| Dyslipidemia                | 17 (21.5)                         | 17 (21.5)                         | 0.787   |
| Malignancy                  | 14 (17.7)                         | 10 (13.9)                         | 0.507   |
| Cardiovascular disease      | 11 (13.9)                         | 9 (12.5)                          | 0.780   |
| Liver cirrhosis             | 6 (7.6)                           | 8 (11.1)                          | 0.471   |
| Cerebrovascular disease     | 4 (5.1)                           | 3 (4.2)                           | 1.000   |
| Chronic lung diseases       | 2 (2.5)                           | 3 (4.2)                           | 0.671   |
| Intravenous drug use        | 0 (0)                             | 3 (4.2)                           | 0.108   |
| Prior hospitalization within 90 days | 31 (35.2) | 32 (39.5) | 0.565   |
| Prior antibiotics use within 90 days | 19 (21.6) | 19 (23.5) | 0.772   |
| Beta-lactams                |                                   |                                   |         |
| Oxacillin                   | 1 (1.1)                           | 3 (3.7)                           | 0.284   |
| Amoxicillin or ampicillin   | 2 (2.2)                           | 2 (2.5)                           | 1.000   |
| Amoxicillin/clavulanic acid | 1 (1.1)                           | 0 (0)                             | 1.000   |
| Piperacillin/tazobactam     | 7 (8.0)                           | 5 (6.2)                           | 0.768   |
| Cefazolin                   | 5 (5.7)                           | 4 (4.9)                           | 1.000   |
| Ceftriaxone                 | 2 (2.3)                           | 6 (7.4)                           | 0.153   |
| Ertapenem                   | 1 (1.1)                           | 1 (1.2)                           | 1.000   |
| Meropenem                   | 6 (6.8)                           | 4 (4.9)                           | 0.749   |
| Other groups of antibiotics |                                   |                                   |         |
| Vancomycin                  | 6 (6.8)                           | 3 (3.7)                           | 0.499   |
| Fluoroquinolones            | 3 (3.4)                           | 2 (2.5)                           | 0.717   |
| Medical devices             | 28 (31.8)                         | 25 (30.9)                         | 1.000   |
| Central venous catheter     | 17 (19.3)                         | 19 (23.5)                         | 0.512   |
| Urinary catheter            | 3 (3.4)                           | 3 (3.7)                           | 1.000   |
| Endotracheal tube or tracheostomy tube | 5 (5.7) | 3 (3.7) | 0.459 |
| Intercostal drainage        | 3 (3.4)                           | 0 (0)                             | 0.247   |
| Automatic implantable cardioverter defibrillator | 1 (1.1) | 2 (2.5) | 0.608 |
| Prosthetic joint            | 1 (1.1)                           | 1 (1.2)                           | 1.000   |
| Permanent double lumen catheter | 1 (1.1) | 0 (0) | 1.000 |
| Tenckhoff catheter          | 0 (0)                             | 2 (2.5)                           | 0.228   |
| Percutaneous nephrostomy    | 0 (0)                             | 1 (1.2)                           | 0.479   |

Data are presented as the count (%), unless otherwise specified.

2.2. Clinical Characteristics

Overall, fifty-eight patients (34.3%) had concurrent sites of infection. The common concurrent sites were skin and soft tissue (36 patients, 21.3%), bone and joint (35 patients, 20.7%), and respiratory tract (30 patients, 17.7%) (Table 2). Clinical characteristics were similar in both periods, except that the proportion of patients with shock was higher in the pre-intervention period (36.4% vs. 22.2%, \( p = 0.044 \)). Laboratory data were similar in both periods, except for alanine aminotransferase, which was higher in the pre-intervention
period ($p = 0.023$). The proportion of methicillin-susceptible strains was higher in the pre-intervention period ($98.9\%$ vs. $91.4\%$, $p = 0.029$).

### Table 2. Clinical characteristics of patients who had *Staphylococcus aureus* bloodstream infections.

| Clinical Characteristics and Laboratory Findings | Pre-Intervention Period ($n = 88$) | Post-Intervention Period ($n = 81$) | $p$-Value |
|-------------------------------------------------|-------------------------------------|-------------------------------------|-----------|
| Concurrent site of infection                     |                                     |                                     |           |
| • Skin and soft tissue                          | 22 (25.0)                           | 14 (17.3)                           | 0.261     |
| • Bone and joint                                | 15 (17.1)                           | 20 (24.7)                           | 0.257     |
| • Respiratory tract                             | 12 (13.6)                           | 18 (22.2)                           | 0.162     |
| • Deep organ abscess                            | 9 (10.2)                            | 15 (18.5)                           | 0.130     |
| • Urinary tract infection                       | 13 (14.5)                           | 9 (11.1)                            | 0.503     |
| • Infective endocarditis                        | 9 (10.2)                            | 6 (7.4)                             | 0.595     |
| • Infectious aortitis                           | 1 (1.1)                             | 2 (2.5)                             | 0.608     |
| • Central nervous system                        | 1 (1.1)                             | 3 (3.7)                             | 0.351     |
| • Catheter-related bloodstream infection         | 9 (11.1)                            | 9 (10.2)                            | 1.000     |
| Signs                                           |                                     |                                     |           |
| • Body temperature ($^\circ$C)                   | 38.4 (37.5, 39)                     | 38.5 (38, 39.2)                     | 0.106     |
| • Alteration of consciousness                   | 20 (22.7)                           | 18 (22.2)                           | 1.000     |
| • Shock                                         | 32 (36.4)                           | 18 (22.2)                           | 0.044     |
| • Respiratory rate $\geq$ 20/min                | 63 (71.6)                           | 50 (61.7)                           | 0.174     |
| Laboratory                                      |                                     |                                     |           |
| • Hematocrit (%)                                | 30.3 ± 7.0                          | 30.1 ± 7.4                          | 0.900     |
| • Hematocrit ≤ 30%                              | 48 (54.5)                           | 42 (51.9)                           | 0.726     |
| • White blood cell (cell/cu.mm.)                 | 12,575                              | 12,160                              | 0.934     |
| • Neutrophil (%)                                | 86 (75.2, 91.9)                     | 89 (82.2, 91.5)                     | 0.095     |
| • Platelets (/cu.mm.)                           | 178,000                             | 190,000                             | 0.932     |
| • Creatinine (mg/dL)                            | 1.5 (0.8, 4.9)                      | 2.5 (1.0, 6.3)                      | 0.158     |
| • Albumin (mg/dL)                               | 3.1 (2.6, 3.6)                      | 3.1 (2.6, 3.7)                      | 0.906     |
| • Albumin $\leq$ 2.5 mg/dL                       | 13 (14.8)                           | 15 (18.5)                           | 0.609     |
| • Alanine aminotransferase (IU/L)                | 30 (19, 54)                         | 23 (13, 33)                         | 0.023     |
| • Total bilirubin (mg/dL)                        | 0.9 (0.4, 1.6)                      | 0.7 (0.4, 1.5)                      | 0.539     |
| Complicated bloodstream infection                | 30 (34.1)                           | 32 (29.5)                           | 0.466     |
| Blood culture that grew MSSA                     | 87 (98.9)                           | 74 (91.4)                           | 0.029     |
| Vancomycin MIC of MRSA (mg/L)                    | 1 ($n = 1$ patient)                 | 1 (0.5, 1) ($n = 7$ patients)        | 0.564     |

Data are presented as count (%), unless otherwise specified. cu.mm., cubic millimeter; mg/dL, milligrams per deciliter; IU/L, international unit per liter; mg/L, milligrams per liter; MIC, minimum inhibitory concentration; MRSA, methicillin-resistant *S. aureus*; MSSA, methicillin-susceptible *S. aureus*.

### 2.3. Process Measures after Implementation of SA-BSI Treatment Protocol

The appropriateness of the management of patients who had SA-BSI increased significantly in the post-intervention period (Table 3) in terms of both nonpharmacologic and antibiotic management.

#### 2.3.1. Nonpharmacologic Management

First, radiologic imaging was carried out significantly more often in the post-intervention period including echocardiography ($70.5\%$ vs. $91.4\%$, $p = 0.001$) (especially trans-thoracic echocardiography), magnetic resonance imaging (MRI) ($10.2\%$ vs. $25.9\%$, $p = 0.002$), and computerized tomography (CT) scans ($5.7\%$ vs. $24.7\%$, $p = 0.049$). Other details regarding radiologic imaging are shown in Table 3.
Table 3. Outcomes and management for patients before and after implementation of *Staphylococcus aureus* bloodstream infection treatment protocol.

| Outcomes                                                  | Pre-Intervention Period | Post-Intervention Period | p-Value |
|-----------------------------------------------------------|-------------------------|--------------------------|---------|
|                                                           | Total = 88 Cases        | Total = 81 Cases         |         |
| 90-day mortality                                         | 30 (34.1)               | 22 (27.2)                | 0.329   |
| Recurrent *S. aureus* bloodstream infection               | 5 (5.7)                 | 1 (1.2)                  | 0.213   |
| Recurrent within 90 days                                  | 0 (0)                   | 0 (0)                    | NA      |
| Recurrent within 1 year                                   | 2 (2.3)                 | 1 (1.2)                  | 1.000   |
| Echocardiography                                          | 62 (70.5)               | 74 (91.4)                | 0.001   |
| Trans-thoracic echocardiography (TTE)                    | 60 (68.2)               | 73 (90.1)                | 0.001   |
| Days of TEE from the first blood culture positivity       | 5 (3, 8) *(n = 60 patients)* | 6 (4, 8) *(n = 73 patients)* | 0.209   |
| Trans-esophageal echocardiography (TEE)                   | 6 (6.8)                 | 8 (9.9)                  | 0.471   |
| Days of TEE from the first blood culture positivity       | 6.5 (6, 8) *(n = 6 patients)* | 8 (5, 13.5) *(n = 8 patients)* | 0.788   |
| Other radiologic imaging                                  | 16 (18.2)               | 32 (39.5)                | 0.002   |
| Magnetic resonance imaging                                | 9 (10.2)                | 21 (25.9)                | 0.009   |
| Spine                                                     | 9 (10.2)                | 20 (24.7)                | 0.013   |
| Thigh                                                     | 0 (0)                   | 1 (1.2)                  | 0.479   |
| Computerized scan                                         | 5 (5.7)                 | 12 (14.8)                | 0.049   |
| Abdomen                                                   | 3 (3.4)                 | 10 (12.3)                | 0.041   |
| Chest                                                     | 2 (2.3)                 | 2 (2.5)                  | 1.000   |
| Ultrasoundography                                          | 6 (6.8)                 | 6 (7.4)                  | 1.000   |
| Arterio-venous fistula                                    | 6 (6.8)                 | 3 (3.7)                  | 0.499   |
| Abdomen                                                   | 1 (1.1)                 | 0 (0)                    | 1.000   |
| Muscle                                                    | 0 (0)                   | 1 (1.2)                  | 0.479   |
| Joint                                                     | 0 (0)                   | 1 (1.2)                  | 0.479   |
| Source control                                            | 30 (34.1)               | 35 (43.2)                | 0.223   |
| Removal of central venous catheter                        | 13 (14.8)               | 12 (14.8)                | 0.994   |
| Debridement                                               | 11 (12.5)               | 12 (14.8)                | 0.661   |
| Drainage                                                  | 10 (11.4)               | 12 (14.8)                | 0.505   |
| Valvular surgery                                           | 3 (3.4)                 | 0 (0)                    | 0.247   |
| Removal of automatic implantable cardioverter defibrillator | 0 (0)                   | 1 (1.2)                  | 0.479   |
| Removal of percutaneous nephrostomy                       | 0 (0)                   | 1 (1.2)                  | 0.479   |
| Days of intravenous antibiotics, median (IQR)             | 14 (7, 18)              | 15 (14, 28)              | 0.015   |
| Intravenous antibiotics ≥ 14 days                         | 53 (60.2)               | 64 (79)                  | 0.007   |
| Afebrile at 72 h after treatment                          | 50 (56.8)               | 48 (59.3)                | 0.271   |
| Follow-up blood culture at 72 h after treatment           | 73 (83)                 | 77 (95.1)                | 0.013   |
| Intravenous antibiotics for treatment of SA-BSI *         |                        |                          |         |
| Cloxacillin                                               | 45 (51.1)               | 57 (70.4)                | 0.011   |
| Piperacillin/tazobactam                                   | 11 (12.5)               | 0                        | 0.001   |
| Cefazolin                                                 | 9 (10.2)                | 4 (4.9)                  | 0.197   |
| Ceftriaxone                                               | 10 (11.4)               | 2 (2.5)                  | 0.025   |
| Meropenem/imipenem                                        | 4 (4.5)                 | 4 (4.9)                  | 1.000   |
| Vancomycin                                                | 9 (10.2)                | 14 (17.3)                | 0.181   |
| Appropriateness of antibiotics use                        | 37 (42.0)               | 66 (81.5)                | <0.001  |
| Right drug                                                | 64 (72.7)               | 75 (92.6)                | 0.001   |
| Right dose                                                | 57 (64.8)               | 73 (90.1)                | <0.001  |
| Right duration                                            | 46 (52.3)               | 73 (90.1)                | <0.001  |
| Right route                                               | 75 (85.2)               | 78 (96.3)                | 0.014   |
| Infectious disease (ID) consultation                      | 44 (50.0)               | 46 (56.8)                | 0.377   |
| ID consultation for complicated bloodstream infection      | 26/33 (78.8)            | 28/38 (73.7)             | 0.781   |
| ID consultation for uncomplicated bloodstream infection    | 18/55 (32.7)            | 18/43 (41.9)             | 0.402   |

Data are presented as count (%), unless otherwise specified. * Two patients and no patients in the pre- and post-intervention periods, respectively, received oral dicloxacillin (p-value = 0.498).

Second, follow-up blood culture at 72 h after treatment was performed more often in the post-intervention period (83% vs. 95.1%, *p* = 0.013).

Third, the infectious disease consultation rate was similar in both periods (50% vs. 56.8%, *p* = 0.377). The ID consultation rate for complicated SA-BSI in the post-intervention period was 73.7%; for optional ID consultation for uncomplicated SA-BSI in the post-intervention period, it was 41.9%.

Forth, source control was no different between the pre- and post-intervention periods (34.1 vs. 43.2%).
2.3.2. Pharmacologic Management
Antibiotic Prescription

Antibiotics prescribed for the treatment of SA-BSI included cloxacillin, cefazolin, piperacillin/tazobactam, meropenem, imipenem/cilastatin, and vancomycin, as shown in Table 3. Cloxacillin was more likely to be prescribed, ceftriaxone was less likely to be prescribed, and no patients received piperacillin/tazobactam in the post-intervention period. However, rather than looking at specific drugs in detail, we aimed to evaluate the appropriateness of antibiotic prescription, as described in Section “Appropriateness of Antibiotic Prescription”.

Appropriateness of Antibiotic Prescription

When looking at each component of appropriateness of antibiotic prescription, we found the following: right drug (72.7% vs. 92.6%, \( p = 0.001 \)), right dose (64.8% vs. 90.1%, \( p < 0.001 \)), right route (85.2% vs. 96.3%, \( p = 0.014 \)), and right duration (52.3% vs. 90.1%, \( p < 0.001 \)) which were higher in the post-intervention period. The appropriateness of antibiotic prescription which included all components was also higher in the post-intervention period (42% vs. 81.5%, \( p < 0.001 \)). The number of patients who received intravenous antibiotics for more than 14 days was significantly higher in the post-intervention period (60.2% vs. 79%, \( p = 0.007 \)).

Factors associated with the overall antibiotic appropriateness from the multivariate analysis were ID consultation (OR 15.5; 95% CI = 5.9–40.8, \( p < 0.001 \)), being in the post-intervention period (OR 9.4; 95% CI: 3.5–25.1, \( p < 0.001 \)), and thorough investigations for metastatic infection foci (OR 7.2; 95% CI 2.1–25.2, \( p = 0.002 \)).

2.4. Outcomes Measures after Implementation of SA-BSI Treatment Protocol

Overall, the 90-day mortality was 30% (52 patients). However, mortality attributable to SA-BSI (case-fatality rate) was 20.1% (34 patients). Twenty patients died from other causes: *Acinetobacter baumannii* infections including pneumonia with respiratory failure (four), bloodstream infection (one), and urinary tract infection (one); non-CNS bleeding (four); cardiovascular conditions (two); candidemia (two); lung cancer (one); intracerebral hemorrhage (one); chronic liver disease (one); hospital-acquired pneumonia with respiratory failure from an unidentified pathogen (one).

As the primary objective was to determine overall mortality, we compared overall mortality between the two periods. The mortality rate was 34.1% and 27.2% in the pre- and post-intervention periods, respectively (\( p = 0.329 \)) (Table 3). The patients who died were older, were more likely to be admitted to the medical intensive care unit, and were more likely to have hypertension, dyslipidemia, malignancy, cardiovascular disease, respiratory tract infections, and hypoalbuminemia. On the other hand, patients who survived were more likely to have skin and soft tissue infections and source control (especially drainage), received intravenous antibiotics for at least 14 days, and received appropriate antibiotic prescriptions (Table 4).

The factors associated with mortality from the multivariate analysis were the presence of alteration of consciousness at first presentation (OR 11.24; 95% CI: 3.96–31.92, \( p < 0.001 \)), having a malignancy as an underlying disease (OR 6.64; 95% CI: 1.83–24.00, \( p = 0.004 \)), albumin \( \leq 2.5 \) mg/dL at first presentation (OR 5.23; 95% CI: 1.71–16.02, \( p = 0.004 \)), and having a respiratory tract infection (OR 5.07; 95% CI: 1.53–16.84, \( p = 0.008 \)). Drainage source of infection was the only factor that reduced risk of death (OR 0.08; 95% CI: 0.01–0.53, \( p = 0.009 \)).

Recurrent SA-BSI was rare (three patients, 1.8%), and thus no further analysis was conducted relating to this outcome.
Table 4. Comparison of the characteristics of patients with *Staphylococcus aureus* bloodstream infections who survived and who died.

| Characteristics                          | Patients Who Survived (n = 117) | Patients Who Died (n = 52) | p-Value |
|------------------------------------------|---------------------------------|----------------------------|---------|
| Male                                     | 72 (61.5)                       | 30 (57.7)                  | 0.637   |
| Age ≥ 60 years old                      | 63 (53.8)                       | 40 (76.9)                  | 0.005   |
| Unit of admission                        |                                 |                            |         |
| General internal medicine                | 78 (66.7)                       | 27 (51.9)                  | 0.068   |
| Medical intensive care                   | 9 (7.7)                         | 17 (32.7)                  | <0.001  |
| General surgery                          | 17 (14.5)                       | 3 (5.8)                    | 0.104   |
| Surgical intensive care                  | 4 (3.4)                         | 2 (3.8)                    | 1.000   |
| General orthopedic                       | 8 (6.8)                         | 3 (5.8)                    | 0.104   |
| Underlying diseases                      |                                 |                            |         |
| Hypertension                             | 45 (38.5)                       | 30 (57.7)                  | 0.020   |
| End-stage renal disease                  | 50 (42.7)                       | 16 (30.8)                  | 0.141   |
| Diabetes mellitus                        | 38 (32.5)                       | 19 (36.5)                  | 0.606   |
| Dyslipidemia                             | 17 (14.5)                       | 17 (32.7)                  | 0.007   |
| Malignancy                               | 12 (10.3)                       | 12 (23.1)                  | 0.028   |
| Cardiovascular disease                   | 10 (8.5)                        | 10 (19.2)                  | 0.047   |
| Liver cirrhosis                          | 11 (9.4)                        | 3 (5.8)                    | 0.554   |
| Cerebrovascular disease                  | 4 (3.4)                         | 3 (5.0)                    | 0.677   |
| Chronic lung diseases                    | 2 (1.7)                         | 2 (3.8)                    | 0.588   |
| Prior hospitalization within 90 days     | 44 (37.6)                       | 19 (36.5)                  | 0.895   |
| Prior antibiotics use within 90 days     | 27 (23.1)                       | 11 (21.2)                  | 0.782   |
| Medical devices                          | 36 (30.8)                       | 17 (32.7)                  | 0.804   |
| Concurrent site of infection             |                                 |                            |         |
| Skin and soft tissue                     | 31 (26.5)                       | 5 (9.6)                    | 0.013   |
| Bone and joint                           | 27 (23.1)                       | 8 (15.4)                   | 0.255   |
| Respiratory tract                        | 14 (12.0)                       | 16 (30.8)                  | 0.003   |
| Deep organ abscess                       | 20 (17.1)                       | 4 (7.7)                    | 0.106   |
| Urinary tract infection                  | 13 (11.1)                       | 9 (17.3)                   | 0.269   |
| Infective endocarditis                   | 9 (10.2)                        | 6 (7.4)                    | 0.595   |
| Infectious aortitis                      | 1 (0.9)                         | 2 (3.9)                    | 0.224   |
| Central nervous system                   | 2 (1.7)                         | 2 (3.9)                    | 0.588   |
| Catheter-related bloodstream infection   | 14 (12.0)                       | 4 (7.7)                    | 0.406   |
| Signs                                     |                                 |                            |         |
| Body temperature (°C)                    | 38.5 (38, 39)                   | 38.4 (37.4, 39)            | 0.102   |
| Alteration of consciousness              | 13 (11.1)                       | 25 (48.1)                  | <0.001  |
| Shock                                    | 31 (35.2)                       | 19 (23.5)                  | 0.187   |
| Respiratory rate ≥ 20/min                | 70 (79.5)                       | 43 (53.1)                  | 0.004   |
| Laboratory                                |                                 |                            |         |
| Hematocrit (%)                           | 31 (7)                          | 28.3 (7.3)                 | 0.023   |
| Hematocrit ≤ 30%                         | 57 (48.7)                       | 33 (63.5)                  | 0.076   |
| White blood cell (cell/cu.mm.)           | 12,880                          |                            |         |
| Neutrophil (%)                           | 87 (78.9, 91.5)                 | 89 (78.2, 91.8)            | 0.967   |
| Platelets (/cu.mm.)                      | 392,000                         |                            |         |
| Creatinine (mg/dL)                       | 1.4 (0.8, 6.6)                  | 1.8 (1.1, 3.3)             | 0.158   |
| Albumin (mg/dL)                          | 3.3 (2.7, 3.8)                  | 2.8 (2.1, 3.3)             | <0.001  |
| Albumin ≤ 2.5 mg/dL                      | 11 (9.4)                        | 17 (32.7)                  | 0.001   |
| Alanine aminotransferase (IU/L)          | 24 (15.5, 40.5)                 | 29 (17.54)                 | 0.394   |
| Total bilirubin (mg/dL)                  | 0.6 (0.4, 1.4)                  | 0.8 (0.5, 2.1)             | 0.122   |
| Complicated bloodstream infection         | 42 (35.9)                       | 20 (38.5)                  | 0.750   |
| Source control                           | 53 (45.3)                       | 12 (23.1)                  | 0.006   |
| Removal of central venous catheter       | 20 (17.1)                       | 5 (9.6)                    | 0.206   |
| Debridement                              | 18 (15.4)                       | 5 (9.6)                    | 0.024   |
| Drainage                                 | 20 (17.1)                       | 2 (3.8)                    | 0.024   |
| Valvular surgery                         | 2 (1.7)                         | 1 (1.9)                    | 1.000   |
Table 4. Cont.

| Characteristics                                      | Patients Who Survived (n = 117) | Patients Who Died (n = 52) | p-Value |
|------------------------------------------------------|---------------------------------|---------------------------|---------|
| Days of intravenous antibiotics, median (IQR)        | 14.5 (14, 28)                   | 8 (5, 15)                 | <0.001  |
| Received intravenous antibiotics ≥ 14 days           | 97 (82.9)                      | 20 (38.5)                 | <0.001  |
| Follow-up blood culture at 72 h after treatment      | 108 (92.3)                     | 42 (80.8)                 | 0.028   |
| Afebrile at 72 h after treatment                     | 76 (65.0)                      | 22 (42.4)                 | 0.126   |
| Appropriateness of antibiotic use                    | 80 (68.4)                      | 23 (44.2)                 | 0.003   |
| Right drug                                           | 103 (88)                       | 36 (69.2)                 | 0.003   |
| Right dose                                           | 95 (81.2)                      | 35 (67.3)                 | 0.048   |
| Right duration                                       | 95 (81.2)                      | 24 (46.2)                 | <0.001  |
| Right route                                          | 104 (88.9)                     | 49 (94.2)                 | 0.396   |
| Infectious disease consultation                      | 66 (56.4)                      | 24 (46.2)                 | 0.217   |
| Being in the post-intervention period                | 59 (50.4)                      | 22 (42.3)                 | 0.329   |

Data are presented as the count (%), unless otherwise specified. cu.mm., cubic millimeter; mg/dL, milligrams per deciliter; IU/L, international unit per liter; mg/L, milligrams per liter.

2.5. Post Hoc Analysis

This study was not planned to evaluate the impact of ID consultation in addition to the implementation of a hospital-wide protocol. However, as the rate of ID consultation was not different between the two periods and the overall consultation rate was 53.3%, we further analyzed the impact of ID consultation on the management of patients with SA-BSI.

From the multivariate analysis, ID consultation was frequently performed in patients who had complicated SA-BSI (OR 6.2; 95% CI: 2.6–14.5, \( p < 0.001 \)). ID consultation frequently led to echocardiography (OR 3.9; 95% CI: 1.2–12.5, \( p = 0.023 \)) and appropriate antibiotic prescription (OR 7.2; 95% CI: 3.1–16.7, \( p < 0.001 \)).

However, ID specialists were less frequently consulted when a patient was admitted to the intensive care unit (OR 0.3; 95% CI 0.1–0.8, \( p = 0.022 \)).

3. Discussion

This study demonstrated that the implementation of a treatment protocol for SA-BSI improved the quality of care. The radiologic imaging rate, follow-up blood culture rate, and appropriateness of antibiotic prescription were significantly increased in the post-intervention period, which is concordant with previous reports [5,7–9,11–14]. This intervention raised awareness among physicians at the hospital of SA-BSI. A clear and concise protocol may guide non-ID physicians to properly manage patients with SA-BSI.

Despite the improvement in the appropriateness of antibiotic prescription in terms of the right drug, right dose, right route, and right duration and thorough investigations to determine whether the patients had metastatic infections, including echocardiography and radiologic imaging (i.e., MRI of the spine and CT scans of the abdomen), we failed to demonstrate a significant reduction in mortality (34% in pre-intervention vs. 27% in post-intervention, \( p\)-value = 0.329) or recurrent infection.

Most studies that implemented protocols to treat patients with SA-BSI show improved quality of care and decreased mortality if the protocol was adhered to [5–7,9,11–13]. The majority of these studies incorporated ID consultation into the protocol. Their results show that ID specialists play an important role and reduce mortality in patients with SA-BSI. However, some studies did not show a significant reduction in mortality rate, even when there was an improvement in antibiotic appropriateness and source control [8,14]. These studies implemented and monitored adherence to the protocol but did not mandate consultations with ID specialists in the post-intervention period, similar to our study. In the authors’ view, along with previous studies [5,7–9,11–14], a hospital-wide protocol that includes ID consultation is recommended.

This study was designed to guide non-ID physicians to manage patients with uncomplicated SA-BSI properly with optional ID consultation. On the other hand, ID consultation is recommended for patients with complicated SA-BSI. However, ID consultation was...
adhered to in complicated SA-BSI in only 74% of cases in the post-intervention period. The appropriateness of antibiotic prescription was associated with ID consultation, being in the post-intervention period (hospital-wide protocol implementation), and thorough investigation for metastatic infections (with indirectly reflected appropriate treatment duration and source control). Interestingly, ID specialists were less involved in the care of patients that developed SA-BSI in the ICU. The reasons for this need to be further explored.

In this study, the factors associated with mortality were related to host factors and severe infection. These factors included alteration of consciousness at first presentation, having a malignancy as an underlying disease, hypoalbuminemia (albumin ≤2.5 mg/dL) at first presentation, and having a concurrent respiratory infection. The alteration of consciousness may represent an acute brain dysfunction from sepsis [15]. Patients who had a malignancy had a higher risk for infection, subsequent complications, and death [16]. Low albumin may represent a greater severity of illness [17]. Those with a concurrent respiratory tract infection had a high prevalence of septic shock [18]. On the other hand, drainage source of infection can reduce mortality. Patients who underwent source control had a lower mortality rate than patients who did not [19].

In addition, previous studies have reported that factors associated with mortality in SA-BSI consisted of old age [2,3], multiple comorbidities [4], ICU admission [4], previous exposure to antibiotics [4], methicillin-resistant *S. aureus* (MRSA) bloodstream infection [3,4], septic shock [3], liver cirrhosis [3], inappropriate empiric antibiotic treatment, and not receiving an ID consultation [3].

In this study, one-fifth and one-fourth of patients in the pre- and post-intervention periods, respectively, were exposed to antibiotics within 3 months prior to the occurrence of SA-BSI; however, this factor was not associated with treatment outcome. In addition, previous studies have reported that prior exposure to third-generation cephalosporins and fluoroquinolones was associated with MRSA infection [20–24]. We also found a higher proportion of methicillin-resistant strains in patients who had been exposed to antibiotics compared with those who had not (13.2%; 5 of 38 vs. 2.3%; 3 of 131, *p*-value = 0.015). However, nine patients who had been exposed to vancomycin had methicillin-susceptible *S. aureus* (MSSA) BSI.

The strength of this study lies in the fact that the treatment protocol may be applied to a hospital where infectious disease specialists are not available. Although this study did not demonstrate a death reduction, the patient management improved significantly in terms of the appropriateness of antibiotics, follow-up blood culture, and attempt to discover metastatic infections.

This study had several limitations. First, the mortality rate appeared to be 34% and 27% in the pre- and post-intervention periods, which were different from the number used for the sample size calculation (40% and 20% for the pre- and post-intervention periods). If this was the case, a larger sample size may be required to detect the difference in the mortality rate. Second, this study was not designed to measure real-time protocol adherence in the post-intervention period, as this was one of the programs for quality improvement and patient safety. However, we performed the process measure including protocol adherence after implementing the protocol as presented in this study. Measuring protocol adherence helped to determine the room for improvement.

One may be concerned about the impact of the COVID-19 pandemic on this study’s results. The first COVID-19 case at the Maharaj Nakorn Chiang Mai Hospital was documented in the third week of January 2020, and the hospital policy then reduced the number of admissions for nonemergency conditions, including nonemergency surgeries and procedures, in March 2020. However, we continued to service patients who required hospitalization. In addition, the number of patients with SA-BSI was similar to the hospital’s annual reports since 2013 (data from the Diagnostic Laboratory, Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand). Only one patient with COVID-19 in the post-intervention period had SA-BSI, who had an ID consultation and survived. Therefore, if COVID-19 did affect our results, its effects were minimal and similar in both periods.
4. Materials and Methods

A retrospective pre-post intervention study was conducted in patients aged ≥18 years old who were admitted to Maharaj Nakorn Chiang Mai Hospital, including the internal medicine, surgery, and orthopedic wards, and had *S. aureus* grow from a blood culture in at least one bottle during the study period. The pre-intervention period was the period one year before implementing the intervention (1 October 2019 to 30 September 2020). The post-intervention period was during the one year after implementing the intervention (1 November 2020 to 31 October 2021). October 2020 was the protocol’s implementation period.

**Implementation of intervention:**

1. ID specialists developed a hospital-wide SA-BSI management protocol. The protocol was adapted from evidence-based data and standard treatment guidelines [20–23]. The treatment protocol is shown in Supplementary Materials Figure S1;
2. A conference with the primary care team who had a role in the treatment of SA-BSI was held at the Department of Internal Medicine, Surgery, and Orthopedics. The conference described the appropriate management of SA-BSI and explained how to follow the hospital-wide SA-BSI management protocol;
3. The protocol was available at the point of care;
4. We monthly reminded the staff of the treatment protocol in patient care team conferences.

Data collection included demographic and clinical characteristics, treatment outcome, and details of antibiotic prescription.

**Definitions** [24,25]:

1. MSSA is *S. aureus* that is susceptible to methicillin;
2. MRSA is *S. aureus* that is resistant to methicillin. *S. aureus* isolates were tested using a disk diffusion method following the Clinical and Laboratory Standards Institute (CLSI) guidelines, M02-A12 (CLSI, 2015), against four antibiotics, namely, erythromycin (15 µg), clindamycin (2 µg), oxacillin (30 µg cefoxitin as a surrogate drug) with a zone diameter ≥22 mm interpreted as methicillin-susceptible (MS) and ≤21 mm as methicillin-resistant (MR), and trimethoprim/sulfamethoxazole (1.25 µg/23.75 µg), (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) [24].
3. Complicated SA-BSI: SA-BSI with one of the following: (1) infective endocarditis; (2) bone and joint infections; (3) metastatic foci of infections, e.g., deep organ abscess; (4) neutropenia; (5) persistent bacteremia after 72 h of appropriate antibiotics; (6) persistent fever after 72 h despite appropriate antibiotic; (7) cardiovascular implantable electronic device (CIED) infection; (8) unable to remove central venous catheter [23].
4. The appropriateness of antibiotic prescription was defined as all of the following: right drug, right dose, right route, and right duration for treatment of SA-BSI accounting for history of drug allergy and intolerance.

**Statistical analysis**

Clinical data are presented as the count (%) or median and interquartile range (IQR) where appropriate. Comparisons of demographic data and clinical characteristics between groups were performed using the Student’s *t*-test, Mann–Whitney U test, chi-square test, or Fisher’s exact test where appropriate. Univariate logistic regression analysis was performed to determine the predictors of fatal outcomes. Variables with a *p*-value < 0.10 in the univariate analysis were then tested in a multivariate logistic regression model using a backward stepwise procedure. A two-sided test with a significance level of *p* < 0.05 was used to determine statistical significance. All statistical analyses were performed using Stata statistical software, version 14 (Stata Statistical Software: Release 14, Stata Corporation, College Station, TX, USA).

**Sample size calculation**

This study was part of a quality improvement and patient safety program. Therefore, we planned to enroll all patients who met the inclusion criteria in both periods. However, to detect the reduction in the mortality rate (the primary outcome) from 40% in the pre-intervention period [1,2] to 20% in the post-intervention period [7], with a power of 80%
and a two-sided alpha of 0.05, at least 79 cases per group was required. Therefore, the sample size needed to be 158 cases or more.

5. Conclusions

A treatment protocol involving thorough investigations for metastatic infections, follow-up blood culture at 72 h after treatment, and appropriate antibiotic prescription significantly improved the quality of care for patients with SA-BSI. However, the mortality rate did not decrease. A hospital-wide protocol with recommended ID consultation may help to improve patient outcomes.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/antibiotics11060827/s1, Figure S1: The hospital-wide protocol for S. aureus bloodstream infection.

Author Contributions: Conceptualization, R.C.; methodology, R.C.; formal analysis, S.Y.; resources, K.K. and P.K.; data curation, K.K.; writing—original draft preparation, K.K.; writing—review and editing, R.C.; visualization, K.K. and P.K.; supervision, R.C. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the Faculty of Medicine, Chiang Mai University, by the Research Ethics Committee No. 4 (approval number: MED-2564-08685).

Informed Consent Statement: Patient consent was waived as the implementation of the treatment protocol was part of a quality improvement program for patient safety. The data were retrospectively collected.

Data Availability Statement: Some of the data will be shared upon request.

Conlicts of Interest: The authors declare no conflict of interest.

References

1. Hassoun, A.; Linden, P.K.; Friedman, B. Incidence, prevalence, and management of MRSA bacteremia across patient populations- a review of recent developments in MRSA management and treatment. Crit. Care 2017, 21, 211. [CrossRef] [PubMed]
2. Van Hal, S.J.; Jensen, S.O.; Vaska, V.L.; Espedido, B.A.; Paterson, D.L.; Gospell, I.B. Predictors of mortality in Staphylococcus aureus Bacteremia. Clin. Microbiol. Rev. 2012, 25, 362–386. [CrossRef] [PubMed]
3. Bassetti, M.; Righi, E.; Del Giacomo, P.; Sartor, A.; Ansaldi, F.; Trucchi, C.; Alicino, C.; Trecarichi, E.M.; Spanu, T.; Paganino, C.; et al. Predictors of Mortality with Staphylococcus aureus Bacteremia in Elderly Adults. J. Am. Geriatr. Soc. 2018, 66, 1284–1289. [CrossRef] [PubMed]
4. Yilmaz, M.; Elaldi, N.; Balkan, I.I.; Arslan, F.; Batırel, A.A.; Bakıcı, M.Z.; Gozel, M.G.; Alkan, S.; Çelik, A.D.; Yetkin, M.A.; et al. Mortality predictors of Staphylococcus aureus bacteremia: A prospective multicenter study. Ann. Clin. Microbiol. Antimicrob. 2016, 15, 7. [CrossRef] [PubMed]
5. Hadano, Y.; Kakuma, T.; Matsumoto, T.; Ishibashi, K.; Isoda, M.; Yasunaga, H. Reduction of 30-day death rates from Staphylococcus aureus bacteremia by mandatory infectious diseases consultation: Comparative study interventions with and without an infectious disease specialist. Int. J. Infect. Dis. 2021, 103, 308–315. [CrossRef] [PubMed]
6. Bai, A.; Showler, A.; Burry, L.; Steinberg, M.; Ricciuto, D.R.; Fernandes, T.; Chiu, A.; Raybardhan, S.; Science, M.; Fernando, E.; et al. Impact of Infectious Disease Consultation on Quality of Care, Mortality, and Length of Stay in Staphylococcus aureus Bacteremia: Results From a Large Multicenter Cohort Study. Clin. Infect. Dis. 2015, 60, 1451–1461. [CrossRef] [PubMed]
7. Berger, N.J.; Wright, M.E.; Pouliot, J.D.; Green, M.W.; Armstrong, D.K. The Impact of a Pharmacist-Driven Staphylococcus aureus Bacteremia Initiative in a Community Hospital: A Retrospective Cohort Analysis. Pharmacy 2021, 9, 191. [CrossRef] [PubMed]
8. Bolhuis, K.; Bakker, L.J.; Keijer, J.T.; de Vries, P.J. Implementing a hospital-wide protocol for Staphylococcus aureus bacteremia. Eur. J. Clin. Microbiol. Infect. Dis. 2018, 37, 1553–1562. [CrossRef]
9. Townsend, J.; Pelletier, J.; Peterson, G.; Matulevicius, S.; Sreeramoju, P. Quality Improvement of Staphylococcus aureus Bacteremia Management and Predictors of Relapse-free Survival. Am. J. Med. 2016, 129, 195–203. [CrossRef]
10. Pragman, A.A.; Kuskowski, M.A.; Abraham, J.M.; Filice, G.A. Infectious Disease Consultation for Staphylococcus aureus Bacteremia Improves Patient Management and Outcomes. Infect. Dis. Clin. Pract. 2012, 20, 261–267. [CrossRef]
11. Borde, J.P.; Batin, N.; Rieg, S.; Feik, R.; Reimling, C.; Kern, W.V.; De With, K.; Hübner, J.; Ruhnke, M.; Kaier, K. Adherence to an antibiotic stewardship bundle targeting Staphylococcus aureus blood stream infections at a 200-bed community hospital. Infection 2014, 42, 713–719. [CrossRef] [PubMed]
12. Fowler, V.G., Jr.; Sanders, L.L.; Sexton, D.J.; Kong, L.; Marr, K.A.; Gopal, A.K.; Gottlieb, G.; McClelland, R.S.; Corey, G.R. Outcome of *Staphylococcus aureus* bacteremia according to compliance with recommendations of infectious diseases specialists: Experience with 244 patients. *Clin. Infect. Dis.* 1998, 27, 478–486. [CrossRef] [PubMed]

13. Laupland, K.B.; Steele, L.; Pasquill, K.; Parfitt, E.C. *Staphylococcus aureus* bloodstream infection: Secular changes associated with the implementation of a de novo clinical infectious diseases service in a Canadian population. *Int. J. Infect. Dis.* 2021, 104, 45–49. [CrossRef] [PubMed]

14. Nguyen, C.T.; Gandhi, T.; Chenoweth, C.; Lassiter, J.; Dela-Pena, J.; Eschenauer, G.; Nagel, J.L. Impact of an antimicrobial stewardship-led intervention for *Staphylococcus aureus* bacteraemia: A quasi-experimental study. *J. Antimicrob. Chemother.* 2015, 70, 3390–3396. [PubMed]

15. Sonnevile, R.; Verdonk, F.; Rauturier, C.; Klein, I.F.; Wolff, M.; Annane, D.; Chretien, F.; Sharshar, T. Understanding brain dysfunction in sepsis. *Ann. Intensiv. Care* 2013, 3, 15. [CrossRef] [PubMed]

16. Williams, M.D.; Braun, L.A.; Cooper, L.M.; Johnston, J.; Weiss, R.V.; Qualy, R.L.; Linde-Zwirble, W. Hospitalized cancer patients with severe sepsis: Analysis of incidence, mortality, and associated costs of care. *Crit. Care* 2004, 8, R291–R298. [CrossRef]

17. Atrash, A.K.; de Vasconcellos, K. Low albumin levels are associated with mortality in the critically ill: A retrospective observational study in a multidisciplinary intensive care unit. *S. Afr. J. Crit. Care* 2020, 36, 74–79. [CrossRef]

18. De la Calle, C.; Morata, L.; Cobos-Trigueros, N.; Martinez, J.A.; Cardozo, C.; Mensa, J.; Soriano, A. *Staphylococcus aureus* bacteremic pneumonia. *Eur. J. Clin. Microbiol. Infect. Dis.* 2016, 35, 497–502. [CrossRef]

19. Martínez, M.L.; Ferrer, R.; Torrents, E.; Guillamat-Prats, R.; Gomà, G.; Suárez, D.; Álvarez-Rocha, L.; Pozo-Laderas, J.-C.; Martin-Loeches, I.; Levy, M.M.; et al. Impact of Source Control in Patients With Severe Sepsis and Septic Shock. *Crit. Care Med.* 2017, 45, 11–19. [CrossRef]

20. Chong, Y.P.; Moon, S.M.; Bang, K.-M.; Park, H.J.; Park, S.-Y.; Kim, M.-N.; Park, K.-H.; Kim, S.-H.; Lee, S.-O.; Choi, S.-H.; et al. Treatment duration for uncomplicated *Staphylococcus aureus* bacteraemia to prevent relapse: Analysis of a prospective observational cohort study. *Antimicrob. Agents Chemother.* 2013, 57, 1150–1156. [CrossRef]

21. Holland, T.L.; Arnold, C.; Fowler, V.G., Jr. Clinical management of *Staphylococcus aureus* bacteremia: A review. *JAMA* 2014, 312, 1300–1341. [CrossRef] [PubMed]

22. Liu, C.; Bayer, A.; Cosgrove, S.E.; Daum, R.S.; Fridkin, S.K.; Gorwitz, R.J.; Kaplan, S.L.; Karchmer, A.W.; Levine, D.P.; Murray, B.E.; et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant *Staphylococcus aureus* infections in adults and children. *Clin. Infect. Dis.* 2011, 52, e18–e55. [CrossRef] [PubMed]

23. Merrel, L.A.; Allon, M.; Bouza, E.; Craven, D.E.; Flynn, P.; O'Grady, N.P.; Raad, I.I.; Rijnders, B.J.A.; Sherertz, R.J.; Warren, D.K. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. *Clin. Infect. Dis.* 2009, 49, 1–45. [CrossRef] [PubMed]

24. Clinical and Laboratory Standards Institute (CLSI). *Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard*, 12th ed.; CLSI document M02-A12; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2015.

25. Spivak, E.S.; Cosgrove, S.E.; Srinivasan, A. Measuring Appropriate Antimicrobial Use: Attempts at Opening the Black Box. *Clin. Infect. Dis.* 2016, 63, 1639–1644.